Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Table 1 Demographic and clinical baseline characteristics of all randomized patients with non-squamous NSCLC (maintenance phase a )

From: A randomized, phase 2 study comparing pemetrexed plus best supportive care versus best supportive care as maintenance therapy after first-line treatment with pemetrexed and cisplatin for advanced, non-squamous, non-small cell lung cancer

Characteristic Pemetrexed/BSC (n = 28) BSC alone (n = 27)
Median age (range), years 61 (22-75) 59 (48-83)
Males, n (%) 20 (71.4) 17 (63.0)
Race, n (%)
Caucasian 26 (92.9) 26 (96.3)
African 2 (7.1) 1 (3.7)
ECOG PS, n (%)
0 8 (28.6) 6 (22.2)
1 20 (71.4) 21 (77.8)
Prior therapy, n (%)
Radiotherapy 2 (7.1) 1 (3.7)
Curative surgery 0 (0.0) 2 (7.4)
Disease stageb, n (%)
IIIB 9 (32.1) 10 (37.0)
IV 19 (67.9) 17 (63.0)
Histologic subtype, n (%)
Adenocarcinoma 19 (67.9) 21 (77.8)
Large cell 8 (28.6) 5 (18.5)
Mixed cell 1 (3.6) 1 (3.7)
Smoking status, n (%)
Current smoker 8 (28.6) 6 (22.2)
Former smoker 8 (28.6) 11 (40.7)
Never smoker 12 (42.9) 10 (37.0)
Best tumor response, n (%)c
Complete response (CR) 0 (0.0) 1 (3.7)
Partial response (PR) 10 (35.7) 11 (40.7)
Stable disease (SD) 17 (60.7) 13 (48.1
Unknown 1 (3.6) 2 (7.4)
  1. Abbreviations: BSC = best supportive care; ECOG PS = Eastern Cooperative Oncology Group Performance Status.
  2. Note: The sum of percentages for some characteristics do not add up to 100% due to rounding.
  3. aMaintenance phase was defined as visit 5 to the visit prior to the post-treatment phase (i.e. the data of progression or the start of a new anti-cancer therapy treatment).
  4. bBased on TNM Classification, 6th edition.
  5. cThe best overall tumor response during the induction therapy phase. This was used as the stratification factor for randomization to one of the maintenance phase arms.